ReviewACS pharmacology & translational science2023
Association of COVID-19 with Comorbidities: An Update.
Review in ACS pharmacology & translational science, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 82 citations in OpenAlex.
- Novel Competitive, Nonpeptidic, SARS-CoV‑2 MACS medicinal chemistry letters · 2026Article
- Spatiotemporal and Demographic Patterns of West Nile Neuroinvasive Disease in Vojvodina, Serbia, 2012-2025.Viruses · 2026Article
- Microbiome-Metabolome Crosstalk as a Driver of COVID-19 Severity.Medical sciences (Basel, Switzerland) · 2026Article
- Divergent Inflammatory Profiles but No Predictive Biomarkers of Psychiatric Sequelae After Viral Infection: A 12-Month Cohort Study.International journal of molecular sciences · 2026Article
- Impact of COVID-19 positive status on outcome for individuals with stroke treated in acute inpatient rehabilitation.PM & R : the journal of injury, function, and rehabilitation · 2026Observational
- Secondary infection in severe COVID-19 patients: clinical and microbial patterns at a tertiary hospital in Vietnam.BMC infectious diseases · 2025Article
- Association of COVID-19 Severity with Comorbidities: Results from the World Trade Center Health Registry.International journal of environmental research and public health · 2025Article
- Bicyclic temporin L peptide inhibitors targeting the SARS-CoV-2 main protease: design, synthesis,RSC medicinal chemistry · 2025Article
- Relationship between oxidative stress and COVID-19 severity: A systematic review and meta-analysis.Journal of advanced veterinary and animal research · 2025Article
- The relationship between respiratory tract infections caused by toxin-producing bacteria in burn patients during COVID-19: pathogenesis, diagnostics and novel therapies.Journal of medical microbiology · 2025Review
- Association of vaccination status and immunosuppression with mortality of SARS-CoV-2 infection in patients with fibrotic interstitial lung disease.BMJ open respiratory research · 2025Article
- Association Between Genetic Variants inDiagnostics (Basel, Switzerland) · 2025Article
- Identifying Key Hematological and Biochemical Indicators of Disease Severity in COVID-19 and Non-COVID-19 Patients.Diagnostics (Basel, Switzerland) · 2025Article
- Addressing COVID-19 Vaccine Hesitancy and Uptake Among African Immigrants: Lessons from a Community-Based Outreach Program.Journal of racial and ethnic health disparities · 2025Article
- Article
- Comparative metabolomic analysis reveals shared and unique features of COVID-19 cytokine storm and surgical sepsis.Scientific reports · 2025Article
- Investigating practices and difficulties in communicating with patients about COVID-19 vaccination among healthcare workers in Italy.Scientific reports · 2025Article
- The role of candidate genetic polymorphisms in covid-19 susceptibility and outcomes.BMC medical genomics · 2025Article
- Maternal COVID-19 Infection during Pregnancy among Children Born between 3/2020 and 2/2023 and Potential Disparities.Journal of community medicine & public health · 2025Article
- Exploring Clinical and Imaging Differences in COVID-19: an Observational Approach to the IFITM3 rs12252 Polymorphism.International journal of general medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Coronavirus disease (COVID-19) is caused by severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) which was identified in Wuhan, China in December 2019 and jeopardized human lives. It spreads at an unprecedented rate worldwide, with serious and still-unfolding health conditions and economic ramifications. Based on the clinical investigations, the severity of COVID-19 appears to be highly variable, ranging from mild to severe infections including the death of an infected individual. To add to this, patients with comorbid conditions such as age or concomitant illnesses are significant predictors of the disease's severity and progression. SARS-CoV-2 enters inside the host cells through ACE2 (angiotensin converting enzyme2) receptor expression; therefore, comorbidities associated with higher ACE2 expression may enhance the virus entry and the severity of COVID-19 infection. It has already been recognized that age-related comorbidities such as Parkinson's disease, cancer, diabetes, and cardiovascular diseases may lead to life-threatening illnesses in COVID-19-infected patients. COVID-19 infection results in the excessive release of cytokines, called "cytokine storm", which causes the worsening of comorbid disease conditions. Different mechanisms of COVID-19 infections leading to intensive care unit (ICU) admissions or deaths have been hypothesized. This review provides insights into the relationship between various comorbidities and COVID-19 infection. We further discuss the potential pathophysiological correlation between COVID-19 disease and comorbidities with the medical interventions for comorbid patients. Toward the end, different therapeutic options have been discussed for COVID-19-infected comorbid patients.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.